Intellia Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
NTLA$11.17-7.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | |||
|---|---|---|---|
| (Amounts in thousands except per share data) | |||
| Year Ended December 31, | |||
| 2024 | 2023 | 2022 | |
| Collaboration revenue | $57,877 | $36,275 | $52,121 |
| Operating expenses: | |||
| Research and development | 466,311 | 435,069 | 419,979 |
| General and administrative | 125,829 | 116,497 | 90,306 |
| Total operating expenses | 592,140 | 551,566 | 510,285 |
| Operating loss | (534,263) | (515,291) | (458,164) |
| Other income (expense), net: | |||
| Interest income | 47,807 | 49,832 | 8,542 |
| Change in fair value of investments, net | (32,565) | - | - |
| Loss from equity method investment | - | (15,633) | (11,079) |
| Change in fair value of contingent consideration | - | (100) | (13,485) |
| Total other income (expense), net | 15,242 | 34,099 | (16,022) |
| Net loss | $(519,021) | $(481,192) | $(474,186) |
| Net loss per share, basic and diluted | $(5.25) | $(5.42) | $(6.16) |
| Weighted average shares outstanding, basic and diluted | 98,849 | 88,770 | 76,972 |
| Other comprehensive loss: | |||
| Unrealized gain (loss) on marketable securities | 731 | 3,635 | (1,637) |
| Other comprehensive gain (loss) from equity method investment | - | 1,568 | (3,192) |
| Comprehensive loss | $(518,290) | $(475,989) | $(479,015) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.